Investegate |Ipsen Pharma Announcements | Ipsen Pharma: Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

Investegate announcements from Ipsen Pharma, Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

Related Keywords

Germany ,Saclay ,France General ,France ,Shanghai ,China ,United States ,Paris ,Belgium ,Italy ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Anna Gibbins ,Bakera Clin ,David Loew ,Amy Wolf ,Spraula Orphanet ,Ipsen Euronext ,Feldmanag Neoreviews ,Hopkins Pj Pediatr ,Schatzb Hepatol ,Ioana Piscociu ,Aldriandj Clin ,Lykavierisp Heptology ,Albireo Pharma Inc ,Global Head Of Franchise Communications ,Us Department Of Health ,Head Of Corporate Brand Strategy Communications ,Human Services ,Nasdaq ,Rare Disease ,Albireo Pharma ,Chief Executive Officer ,Priority Review ,Prescription Drug User Fee Act ,Sponsored Level ,American Depositary Receipt ,Franchise Communications ,Corporate Brand Strategy ,French Autorit ,Des March ,Universal Registration Document ,Primary Sclerosing Cholangitis ,Text View ,Res Hepatol ,Investegate Announcements ,Investegate Company Announcements ,Ipsen Pharma ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,